



Oxford Immunotec Global PLC
Investor Relations Department
700 Nickerson Road
Suite 200
Marlborough, MA 01752
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: OXFD


Last Trade:	14.69
Trade Time:	11:15 AM ET Aug 21, 2017
Change:	-0.36 (-2.392%)
Day Range	14.69 - 15.16
52-Week Range	9.49 - 19.51
Volume	33,759

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are a global, high-growth diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary T-SPOT[®] technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body's immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 15, 2017*
[Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares](#)
- Aug 14, 2017*
[Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares](#)
- Aug 1, 2017*
[Oxford Immunotec Reports Second Quarter 2017 Financial Results](#)
- Jul 24, 2017*
[Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer](#)
- Jul 18, 2017*
[Oxford Immunotec Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- Apr 25, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 1, 2017*
[Quarterly Report \(10-Q\)](#)
- May 2, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 1, 2016*
[Quarterly Report \(10-Q\)](#)